Baclofen for binge eating: An open-label trial
Version of Record online: 23 JUL 2007
Copyright © 2007 Wiley Periodicals, Inc.
International Journal of Eating Disorders
Volume 40, Issue 8, pages 687–691, December 2007
How to Cite
Broft, A. I., Spanos, A., Corwin, R. L., Mayer, L., Steinglass, J., Devlin, M. J., Attia, E. and Walsh, B. T. (2007), Baclofen for binge eating: An open-label trial. Int. J. Eat. Disord., 40: 687–691. doi: 10.1002/eat.20434
- Issue online: 29 OCT 2007
- Version of Record online: 23 JUL 2007
- Manuscript Accepted: 13 MAY 2007
- NIMH. Grant Numbers: T32 MH15144, R21 MH65024
- binge eating;
- bulimia nervosa;
- eating disorder;
- clinical trial
Baclofen is a GABA-B agonist that may be useful in the treatment of substance use disorders, and also reduces ‘binge-like’ eating in rodents. We hypothesized that baclofen might be effective in reducing binge eating episodes in binge eating disorder (BED) and bulimia nervosa (BN).
Seven women with BED (n = 4) or BN (n = 3) took baclofen (60 mg/day) for 10 weeks.
Six out of seven patients completed the full 10-week trial. Five out of seven participants (3 BED; 2 BN) demonstrated 50% or greater reduction of frequency of binge eating from beginning to end of the study. Three out of seven participants (2 BED; 1 BN) were free of binge eating at study end. Four out of seven participants elected to continue baclofen at study end. Baclofen was well tolerated by the participants.
In this open-label trial, baclofen was associated with decreased binge eating frequency in patients with BED and BN. © 2007 by Wiley Periodicals, Inc. Int J Eat Disord 2007